An interventional study of Angiographic guided PCI and OCT guided PCI in Ischaemic Heart Disease and Ischemic Heart Disease, sponsored by Aarhus University Hospital Skejby. Active, not recruiting at 38 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Aarhus University Hospital Skejby · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Coronary Artery Disease by Aarhus University Hospital Skejby — none open to participants now, 4 under way, none of them phase 3. Coronary Artery Disease · Aarhus University Hospital Skejby.
Among the 18 studies in Coronary Artery Disease by Aarhus University Hospital Skejby, this one is the 7th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2017, is one of 11 with no phase, and was the 14th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →None of the 18 studies in Coronary Artery Disease by Aarhus University Hospital Skejby is open now. The open studies under Coronary Artery Disease, anywhere →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2017.
This study's enrollment of 1,201 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 425 across the 15 interventional studies, 329 across the 3 observational. Of the 12 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
Aarhus University Hospital Skejby is the lead sponsor of 60 studies on the registry; 3 are open to participants now.
1 of the studies in Coronary Artery Disease by Aarhus University Hospital Skejby that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02973529Aarhus University Hospital SkejbyThe Bioresorbable Implants for Scaffolding Obstructions in Randomized Bifurcations (BIFSORB) Study | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Coronary Artery Disease by Aarhus University Hospital Skejby, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose is to compare median two-year clinical outcome after OCT guided vs. standard guided revascularization of patients requiring complex bifurcation stent implantation
Coronary bifurcation lesions with stenosis in a large side branch may require complex stent implantation techniques with an elevated risk of suboptimal treatment results. Intra vascular optical coherence tomography (OCT) enables improved procedural control of correctable factors and may lead to optimized implantation results.
It is unknown if routine, systematic use of OCT scans during complex bifurcation stenting improves clinical outcome but present available evidence indicates advantages of OCT guidance that could translate into improved clinical outcome.
Hypothesis: Systematic OCT guided revascularization of patients with bifurcation lesions requiring complex stent implantation provides superior two-year clinical outcome compared to standard revascularization by PCI.
Methods: Investigator initiated and investigator sponsored, randomized (1:1), controlled, prospective, multicenter, superiority trial. Randomization is stratified for 1) Left main or non-Left main artery disease, and 2) up-front planned one-stent technique with kissing balloon inflation, or a two-stent technique.
Systematic OCT guidance is detailed for five complex stent implantation techniques. Standard treatment is angiographic based with optional use of intravascular ultrasound (IVUS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Angiographic inclusion criteria:
Functional inclusion criteria:
Functional significance of the main vessel lesion or documented ischemia of the main vessel territory or other objective documentation of lesion significance. Objective evidence of ischemia is required for all treated lesions except for lesions with more than 80% diameter stenosis that may be considered significant.
Procedural inclusion criteria:
Indication for two-stent technique or one-stent technique with kissing balloon inflation
Exclusion Criteria:
Angiographic exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Angiographic guided PCI is revascularization by percutaneous coronary intervention (PCI) and optional use of intravascular ultrasound (IVUS).
Procedure: Angiographic guided PCI
OCT guided PCI is percutaneous coronary intervention (PCI) guided by systematic use of intravascular optical coherence tomography (OCT)
Procedure: OCT guided PCI
Angiographic guided PCI is percutaneous coronary intervention performed by standard angiographic guided techniques
Also known as: PCI, percutaneous transluminal coronary angioplasty (PTCA)
OCT guided PCI is percutaneous coronary intervention (PCI) guided by intra vascular optical coherence tomography (OCT) scans
Also known as: OCT
Combined endpoint of major adverse cardiac events (MACE)
Composite of cardiac death, target lesion myocardial infarction, ischaemic driven target lesion revascularization
Time frame: 24 months
Study bifurcation oriented composite endpoint
Composite of cardiac death, target bifurcation myocardial infarction, target bifurcation revascularisation
Time frame: 1 month
Study bifurcation oriented composite endpoint
Composite of cardiac death, target bifurcation myocardial infarction, target bifurcation revascularisation
Time frame: 12 months
Study bifurcation oriented composite endpoint
Composite of cardiac death, target bifurcation myocardial infarction, target bifurcation revascularisation
Time frame: 24 months
Study bifurcation oriented composite endpoint
Composite of cardiac death, target bifurcation myocardial infarction, target bifurcation revascularisation
Time frame: 36 months
Study bifurcation oriented composite endpoint
Composite of cardiac death, target bifurcation myocardial infarction, target bifurcation revascularisation
Time frame: 48 months
Study bifurcation oriented composite endpoint
Composite of cardiac death, target bifurcation myocardial infarction, target bifurcation revascularisation
Time frame: 60 months
Patient oriented composite endpoint
Composite of all-cause mortality, myocardial infarction, any revascularisation, stroke
Time frame: 1 month
Patient oriented composite endpoint
Composite of all-cause mortality, myocardial infarction, any revascularisation, stroke
Time frame: 12 months
Patient oriented composite endpoint
Composite of all-cause mortality, myocardial infarction, any revascularisation, stroke
Time frame: 24 months
Patient oriented composite endpoint
Composite of all-cause mortality, myocardial infarction, any revascularisation, stroke
Time frame: 36 months
Patient oriented composite endpoint
Composite of all-cause mortality, myocardial infarction, any revascularisation, stroke
Time frame: 48 months
Patient oriented composite endpoint
Composite of all-cause mortality, myocardial infarction, any revascularisation, stroke
Time frame: 60 months
All-cause mortality
Death of any cause including cardiac deaths and non-natural causes of death
Time frame: 1 month
All-cause mortality
Death of any cause including cardiac deaths and non-natural causes of death
Time frame: 12 months
All-cause mortality
Death of any cause including cardiac deaths and non-natural causes of death
Time frame: 24 months
All-cause mortality
Death of any cause including cardiac deaths and non-natural causes of death
Time frame: 36 months
All-cause mortality
Death of any cause including cardiac deaths and non-natural causes of death
Time frame: 48 months
All-cause mortality
Death of any cause including cardiac deaths and non-natural causes of death
Time frame: 60 months
All-cause mortality
Death of any cause including cardiac deaths and non-natural causes of death
Time frame: 120 months
Cardiac death
Death due to cardiac causes or if death is not clearly attributable to other non-cardiac causes
Time frame: 1 month
Cardiac death
Death due to cardiac causes or if death is not clearly attributable to other non-cardiac causes
Time frame: 12 months
Cardiac death
Death due to cardiac causes or if death is not clearly attributable to other non-cardiac causes
Time frame: 24 months
Cardiac death
Death due to cardiac causes or if death is not clearly attributable to other non-cardiac causes
Time frame: 36 months
Cardiac death
Death due to cardiac causes or if death is not clearly attributable to other non-cardiac causes
Time frame: 48 months
Cardiac death
Death due to cardiac causes or if death is not clearly attributable to other non-cardiac causes
Time frame: 60 months
Myocardial infarction
Procedure and non-procedure related myocardial infarction
Time frame: 1 month
Myocardial infarction
Procedure and non-procedure related myocardial infarction
Time frame: 12 months
Myocardial infarction
Procedure and non-procedure related myocardial infarction
Time frame: 24 months
Myocardial infarction
Procedure and non-procedure related myocardial infarction
Time frame: 36 months
Myocardial infarction
Procedure and non-procedure related myocardial infarction
Time frame: 48 months
Myocardial infarction
Procedure and non-procedure related myocardial infarction
Time frame: 60 months
Stent Thrombosis
Definite, possible or probable
Time frame: 1 month
Stent Thrombosis
Definite, possible or probable
Time frame: 12 months
Stent Thrombosis
Definite, possible or probable
Time frame: 24 months
Stent Thrombosis
Definite, possible or probable
Time frame: 36 months
Stent Thrombosis
Definite, possible or probable
Time frame: 48 months
Stent Thrombosis
Definite, possible or probable
Time frame: 60 months
Target lesion myocardial infarction
Myocardial infarction related to an index treated lesion
Time frame: 1 month
Target lesion myocardial infarction
Myocardial infarction related to an index treated lesion
Time frame: 12 months
Target lesion myocardial infarction
Myocardial infarction related to an index treated lesion
Time frame: 24 months
Target lesion myocardial infarction
Myocardial infarction related to an index treated lesion
Time frame: 36 months
Target lesion myocardial infarction
Myocardial infarction related to an index treated lesion
Time frame: 48 months
Target lesion myocardial infarction
Myocardial infarction related to an index treated lesion
Time frame: 60 months
Target lesion revascularisation
Coronary artery bypass grafting or PCI of target lesion
Time frame: 1 month
Target lesion revascularisation
Coronary artery bypass grafting or PCI of target lesion
Time frame: 12 months
Target lesion revascularisation
Coronary artery bypass grafting or PCI of target lesion
Time frame: 24 months
Target lesion revascularisation
Coronary artery bypass grafting or PCI of target lesion
Time frame: 36 months
Target lesion revascularisation
Coronary artery bypass grafting or PCI of target lesion
Time frame: 48 months
Target lesion revascularisation
Coronary artery bypass grafting or PCI of target lesion
Time frame: 60 months
Target bifurcation myocardial infarction
Myocardial infarction related to the index bifurcation
Time frame: 1 month
Target bifurcation myocardial infarction
Myocardial infarction related to the index bifurcation
Time frame: 12 months
Target bifurcation myocardial infarction
Myocardial infarction related to the index bifurcation
Time frame: 24 months
Target bifurcation myocardial infarction
Myocardial infarction related to the index bifurcation
Time frame: 36 months
Target bifurcation myocardial infarction
Myocardial infarction related to the index bifurcation
Time frame: 48 months
Target bifurcation myocardial infarction
Myocardial infarction related to the index bifurcation
Time frame: 60 months
Target bifurcation revascularisation
Coronary artery bypass grafting or PCI of target bifurcation
Time frame: 1 month
Target bifurcation revascularisation
Coronary artery bypass grafting or PCI of target bifurcation
Time frame: 12 months
Target bifurcation revascularisation
Coronary artery bypass grafting or PCI of target bifurcation
Time frame: 24 months
Target bifurcation revascularisation
Coronary artery bypass grafting or PCI of target bifurcation
Time frame: 36 months
Target bifurcation revascularisation
Coronary artery bypass grafting or PCI of target bifurcation
Time frame: 48 months
Target bifurcation revascularisation
Coronary artery bypass grafting or PCI of target bifurcation
Time frame: 60 months
Target vessel revascularisation
Coronary artery bypass grafting or PCI of target vessel
Time frame: 1 month
Target vessel revascularisation
Coronary artery bypass grafting or PCI of target vessel
Time frame: 12 months
Target vessel revascularisation
Coronary artery bypass grafting or PCI of target vessel
Time frame: 24 months
Target vessel revascularisation
Coronary artery bypass grafting or PCI of target vessel
Time frame: 36 months
Target vessel revascularisation
Coronary artery bypass grafting or PCI of target vessel
Time frame: 48 months
Target vessel revascularisation
Coronary artery bypass grafting or PCI of target vessel
Time frame: 60 months
Any revascularisation
Any repeat revascularization except staged revascularization planned during the index procedure
Time frame: 1 month
Any revascularisation
Any repeat revascularization except staged revascularization planned during the index procedure
Time frame: 12 months
Any revascularisation
Any repeat revascularization except staged revascularization planned during the index procedure
Time frame: 24 months
Any revascularisation
Any repeat revascularization except staged revascularization planned during the index procedure
Time frame: 36 months
Any revascularisation
Any repeat revascularization except staged revascularization planned during the index procedure
Time frame: 48 months
Any revascularisation
Any repeat revascularization except staged revascularization planned during the index procedure
Time frame: 60 months
CCS angina class
Canadian Cardiovascular Society (CCS) grading of angina pectoris
Time frame: 1 month
CCS angina class
Canadian Cardiovascular Society (CCS) grading of angina pectoris
Time frame: 12 months
CCS angina class
Canadian Cardiovascular Society (CCS) grading of angina pectoris
Time frame: 24 months
CCS angina class
Canadian Cardiovascular Society (CCS) grading of angina pectoris
Time frame: 36 months
CCS angina class
Canadian Cardiovascular Society (CCS) grading of angina pectoris
Time frame: 48 months
CCS angina class
Canadian Cardiovascular Society (CCS) grading of angina pectoris
Time frame: 60 months
Contrast volume
Contrast volume
Time frame: Baseline, after final baseline procedure
Procedure time
Procedure time
Time frame: Baseline, after final baseline procedure
Fluoroscopy time
Fluoroscopy time
Time frame: Baseline, after final baseline procedure
Number of stents implanted in target lesion
Number of stents implanted in target lesion
Time frame: Baseline, after final baseline procedure
Number of stents implanted in non-target lesion
Number of stents implanted in non-target lesion
Time frame: Baseline, after final baseline procedure
Total stent length in target lesion
Total stent length in target lesion
Time frame: Baseline, just after final baseline procedure
Total stent length in total
Total stent length in total
Time frame: Baseline, just after final baseline procedure
Procedural success
TIMI III flow and less than 30% diameter stenosis in target segments
Time frame: Baseline, just after final baseline procedure
OCT-guiding group: Successful final OCT acquisition in MV
For OCT-guided enrollments. Successful final OCT acquisition in main vessel. Success defined as analyzable stented segment.
Time frame: Baseline, just after final baseline procedure
OCT-guiding group: Successful final OCT acquisition in SB
For OCT-guided enrollments. Successful final OCT acquisition in side branch. Success defined as analyzable stented segment.
Time frame: Baseline, just after final baseline procedure
OCT-guiding group: Successful treatment specific OCT acquisitions
OCT performed succesfully in protocol-defined vessels at all protocol-defined time-points during baseline procedure
Time frame: Baseline, after final baseline procedure
Post-PCI minimal lumen diameter in the stented proximal main vessel segment
Post-PCI minimal lumen diameter by quantitative coronary analysis (QCA) in the stented proximal main vessel segment
Time frame: Baseline, after final baseline procedure
Post-PCI minimal lumen diameter in the stented distal main vessel segment
Post-PCI minimal lumen diameter by quantitative coronary analysis (QCA) in the stented distal main vessel segment
Time frame: Baseline, after final baseline procedure
Post-PCI minimal lumen diameter in the treated side branch vessel segment
Post-PCI minimal lumen diameter by quantitative coronary analysis (QCA) in the treated (stent or balloon) side branch vessel segment
Time frame: Baseline, just after final baseline procedure
Post-PCI minimal lumen diameter in the proximal main vessel edge segment
Post-PCI minimal lumen diameter by quantitative coronary analysis (QCA) in the proximal main vessel edge segment (within 5 mm from the stent)
Time frame: Baseline, just after final baseline procedure
Post-PCI minimal lumen diameter in the distal main vessel edge segment
Post-PCI minimal lumen diameter by quantitative coronary analysis (QCA) in the distal main vessel edge segment (within 5 mm from the stent)
Time frame: Baseline, just after final baseline procedure
Post-PCI minimal lumen diameter in the side branch vessel edge segment
Post-PCI minimal lumen diameter by quantitative coronary analysis (QCA) in the side branch vessel edge segment (within 5 mm from stent or balloon)
Time frame: Baseline, just after final baseline procedure
Post-PCI minimal lumen diameter in the stented bifurcation core segment
Post-PCI minimal lumen diameter by quantitative coronary analysis (QCA) in the stented bifurcation core segment
Time frame: Baseline, after final baseline procedure
Post-PCI minimal lumen diameter in the stented distal main vessel ostium segment
Post-PCI minimal lumen diameter by quantitative coronary analysis (QCA) in the stented distal main vessel ostium segment
Time frame: Baseline, just after final baseline procedure
Post-PCI minimal lumen diameter in the treated side branch vessel ostium segment
Post-PCI minimal lumen diameter by quantitative coronary analysis (QCA) in the treated side branch vessel ostium segment
Time frame: Baseline, just after final baseline procedure
Post-PCI diameter stenosis in the stented proximal main vessel segment
Post-PCI diameter stenosis by quantitative coronary analysis (QCA) in the stented proximal main vessel segment
Time frame: Baseline, just after final baseline procedure
Post-PCI diameter stenosis in the stented distal main vessel segment
Post-PCI diameter stenosis by quantitative coronary analysis (QCA) in the stented distal main vessel segment
Time frame: Baseline, after final baseline procedure
Post-PCI diameter stenosis in the treated side branch vessel segment
Post-PCI diameter stenosis by quantitative coronary analysis (QCA) in the treated (stent or balloon) side branch vessel segment
Time frame: Baseline, after final baseline procedure
Post-PCI diameter stenosis in the proximal main vessel edge segment
Post-PCI diameter stenosis by quantitative coronary analysis (QCA) in the proximal main vessel edge segment (within 5 mm from the stent)
Time frame: Baseline, just after final baseline procedure
Post-PCI diameter stenosis in the distal main vessel edge segment
Post-PCI diameter stenosis by quantitative coronary analysis (QCA) in the distal main vessel edge segment (within 5 mm from the stent)
Time frame: Baseline, just after final baseline procedure
Post-PCI diameter stenosis in the side branch vessel edge segment
Post-PCI diameter stenosis by quantitative coronary analysis (QCA) in the side branch vessel edge segment (within 5 mm from stent or balloon)
Time frame: Baseline, just after final baseline procedure
Post-PCI diameter stenosis in the stented bifurcation core segment
Post-PCI diameter stenosis by quantitative coronary analysis (QCA) in the stented bifurcation core segment
Time frame: Baseline, just after final baseline procedure
Post-PCI diameter stenosis in the stented distal main vessel ostium segment
Post-PCI diameter stenosis by quantitative coronary analysis (QCA) in the stented distal main vessel ostium segment
Time frame: Baseline, just after final baseline procedure
Post-PCI diameter stenosis in the treated side branch ostium segment
Post-PCI diameter stenosis by quantitative coronary analysis (QCA) in the treated side branch ostium segment
Time frame: Baseline, just after final baseline procedure
Post-PCI minimal lumen diameter in non-bifurcation target stented segment
Post-PCI minimal lumen diameter by quantitative coronary analysis (QCA) in non-bifurcation target stented segment
Time frame: Baseline, after final baseline procedure
Post-PCI minimal lumen diameter in non-bifurcation target proximal edge segment
Post-PCI minimal lumen diameter by quantitative coronary analysis (QCA) in non-bifurcation target proximal edge segment (within 5mm fra stent)
Time frame: Baseline, after final baseline procedure
Post-PCI minimal lumen diameter in non-bifurcation target distal edge segment
Post-PCI minimal lumen diameter by quantitative coronary analysis (QCA) in non-bifurcation target distal edge segment (within 5mm fra stent)
Time frame: Baseline, just after final baseline procedure
Post-PCI diameter stenosis in non-bifurcation target stented segment
Post-PCI diameter stenosis by quantitative coronary analysis (QCA) in non-bifurcation target stented segment
Time frame: Baseline, just after final baseline procedure
Post-PCI diameter stenosis in non-bifurcation target proximal edge segment
Post-PCI diameter stenosis by quantitative coronary analysis (QCA) in non-bifurcation target proximal edge segment
Time frame: Baseline, just after final baseline procedure
Post-PCI diameter stenosis in non-bifurcation target distal edge segment
Post-PCI diameter stenosis by quantitative coronary analysis (QCA) in non-bifurcation target distal edge segment
Time frame: Baseline, just after final baseline procedure
Plan to share: Undecided — Is decided after primary endpoint assessment and requires regulatory approval
Ran from Jul 2017 to primary completion in Mar 2022, 56 months.
Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's 56 months is above that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aarhus University Hospital Skejby